Trial · NCT07391709
Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats
NCT07391709, Not applicable, Completed, Trabzon Kanuni Education and Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats. Trials, record NCT07391709. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07391709
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigation of the Protective Effect of Alpha Lipoic Acid on Ischemic Reperfusion Damage in Ischemic Priapism in Rats
- NCT number
- NCT07391709
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 18 participants, actual
- Lead sponsor
- Trabzon Kanuni Education and Research Hospital
- Conditions
- Priapism, Reperfusion Injury
- Interventions
- Ischemic priapism + reperfusion, Ischemic priapism + reperfusion + ALA, Ischemic priapism + reperfusion + ALA
- First posted
- 2026-02-06
- Last updated
- 2026-02-06
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in serum total antioxidant status (TAS) measured by Erel spectrophotometric assay | 7 days after reperfusion | Serum total antioxidant status (TAS) will be measured using the Erel spectrophotometric assay.Unit of Measure mmol Trolox equivalent/L |
| Primary | Change in serum total oxidant status (TOS) measured by Erel spectrophotometric assay | 7 days after reperfusion | Serum total oxidant status (TOS) will be measured using the Erel spectrophotometric assay.Unit of Measure µmol H₂O₂ equivalent/L |
| Primary | Change in serum glutathione peroxidase (GPx) activity measured by spectrophotometric enzyme activity assay | 7 days after reperfusion | Serum glutathione peroxidase (GPx) activity will be measured using a spectrophotometric enzyme activity assay.Unit of Measure U/L |
| Primary | Change in serum malondialdehyde (MDA) concentration measured by ELISA | 7 days after reperfusion | Serum malondialdehyde (MDA) concentration will be measured using a commercial ELISA kit.Unit of Measure ng/mL |
| Primary | Change in serum ischemia-modified albumin (IMA) concentration measured by ELISA | 7 days after reperfusion | Serum ischemia-modified albumin (IMA) concentration will be measured using a commercial ELISA kit.Unit of Measure U/mL |
| Secondary | Change in serum tumor necrosis factor-alpha (TNF-α) concentration measured by ELISA | 7 days after reperfusion | Serum tumor necrosis factor-alpha (TNF-α) concentration will be measured using a commercial ELISA kit.Unit of Measure pg/mL |
| Secondary | Change in penile tissue tumor necrosis factor-alpha (TNF-α) concentration measured by ELISA | 7 days after reperfusion | Penile tissue tumor necrosis factor-alpha (TNF-α) concentration will be measured using a commercial ELISA kit and normalized to tissue protein content.Unit of Measure pg/mg protein |
| Other | Change in GRP78 protein expression in penile tissue measured by immunohistochemistry | 7 days after reperfusion | GRP78 protein expression in penile tissue will be assessed using immunohistochemical semi-quantitative scoring.Unit of Measure Semi-quantitative score |
| Other | Change in CHOP protein expression in penile tissue measured by immunohistochemistry | 7 days after reperfusion | CHOP protein expression in penile tissue will be assessed using immunohistochemical semi-quantitative scoring.Unit of Measure Semi-quantitative score |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07391709
GET https://conductscience.org/api/trials/v1/NCT07391709/registered